Literature DB >> 3161954

Studies on ciprofloxacin therapy of experimental Legionnaires' disease.

R B Fitzgeorge, D H Gibson, R Jepras, A Baskerville.   

Abstract

The concentration of ciprofloxacin in the serum and tissues of normal guinea-pigs was monitored after intramuscular and oral administration. Significant concentrations were attained in the kidneys, but higher doses were required before serum and lung concentrations became measurable. Ciprofloxacin, given parenterally, prevented pyrexia and death of guinea-pigs infected by aerosols of Legionella pneumophila. Although it markedly reduced the number of bacteria in the lungs, it did not prevent the development of pulmonary lesions. Ciprofloxacin administered orally was not so effective in preventing death, although pyrexia was prevented and numbers of bacteria in the lungs of guinea-pigs were reduced. The low minimum inhibitory and bactericidal concentrations of ciprofloxacin against L. pneumophila together with the in vivo results observed suggest that this antibiotic could be of value in the treatment of human beings suffering from Legionnaires' disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161954     DOI: 10.1016/s0163-4453(85)92438-7

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

4.  Efficacy of NY-198 against experimental Legionnaires disease.

Authors:  S Kohno; K Yamaguchi; Y Dohtsu; H Koga; T Hayashi; M Hirota; A Saito; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

6.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 9.  Intracellular distribution and activity of antibiotics.

Authors:  P M Tulkens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.